Thus, the SIRT2-mediated inactivation of p73 is a crucial mechanism in the tumorigenicity of glioblastoma, suggesting that targeting SIRT2 could be a promising therapeutic strategy [71]. The gene discussed is TP73; the disease is glioblastoma.